Primary Objectives:
1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of
methotrexate (MTX) clearance following high dose MTX treatment in patients with a
delayed MTX clearance.
2. To evaluate the pharmacokinetics (PK) of Glucarpidase following high dose MTX treatment
in patients with a delayed MTX clearance.
3. To evaluate the safety profile of Glucarpidase following high dose MTX treatment in
patients with a delayed MTX clearance.
Secondary Objectives:
1. To evaluate the effect of Glucarpidase on the incidence of neutropenic fever and use of
intravenous (IV) antibiotics.
2. To evaluate the effect of Glucarpidase on the length of hospitalization.
3. To evaluate the effect of Glucarpidase on renal function.
4. To evaluate the effect of Glucarpidase on Quality of Life (QOL).
5. To evaluate the anti-glucarpidase antibody response.
6. To evaluate the efficacy of Glucarpidase following its use in repeated cycles of high
dose MTX treatment.